X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (959) 959
Publication (98) 98
Newsletter (90) 90
Newspaper Article (38) 38
Book Review (13) 13
Book Chapter (11) 11
Transcript (11) 11
Dissertation (3) 3
Trade Publication Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pertuzumab (1016) 1016
trastuzumab (610) 610
breast cancer (562) 562
oncology (561) 561
index medicus (542) 542
humans (479) 479
female (402) 402
cancer (325) 325
breast neoplasms - drug therapy (312) 312
chemotherapy (286) 286
her2 (265) 265
open-label (229) 229
lapatinib (217) 217
care and treatment (204) 204
receptor, erbb-2 - metabolism (184) 184
docetaxel (180) 180
research (179) 179
metastasis (177) 177
breast neoplasms - pathology (170) 170
therapy (160) 160
survival (141) 141
antineoplastic combined chemotherapy protocols - therapeutic use (138) 138
middle aged (138) 138
epidermal growth factor (137) 137
skin and connective tissue diseases (137) 137
receptor, erbb-2 - antagonists & inhibitors (133) 133
antineoplastic agents - therapeutic use (129) 129
erbb-2 protein (124) 124
monoclonal-antibody (121) 121
adult (118) 118
aged (117) 117
drug therapy (116) 116
health aspects (114) 114
treatment outcome (113) 113
breast neoplasms - metabolism (110) 110
multicenter (110) 110
safety (106) 106
cancer therapies (104) 104
analysis (103) 103
antibodies, monoclonal, humanized - therapeutic use (102) 102
medicine & public health (101) 101
efficacy (100) 100
animals (99) 99
tumors (97) 97
antibodies, monoclonal, humanized - administration & dosage (95) 95
combination (91) 91
clinical trials (90) 90
women (86) 86
metastatic breast-cancer (85) 85
neoadjuvant therapy (85) 85
receptor, erbb-2 - genetics (85) 85
phase-ii (83) 83
pharmacology & pharmacy (82) 82
adjuvant chemotherapy (81) 81
trial (80) 80
neoplasms (78) 78
oncology, experimental (78) 78
patients (78) 78
metastatic breast cancer (72) 72
trastuzumab - administration & dosage (71) 71
breast-cancer (70) 70
disease-free survival (69) 69
trastuzumab emtansine (69) 69
breast neoplasms - genetics (68) 68
adjuvant treatment (67) 67
monoclonal antibodies (67) 67
growth-factor receptor (66) 66
phase-ii trial (66) 66
hematology, oncology and palliative medicine (64) 64
immunotherapy (64) 64
plus trastuzumab (64) 64
cell line, tumor (63) 63
double-blind (63) 63
metastases (63) 63
neoadjuvant chemotherapy (63) 63
plus (63) 63
paclitaxel (62) 62
pertuzumab plus trastuzumab (62) 62
receptor (62) 62
resistance (61) 61
t-dm1 (61) 61
adjuvant trastuzumab (60) 60
medical research (60) 60
dimerization inhibitor (58) 58
molecular targeted therapy (58) 58
article (56) 56
obstetrics & gynecology (56) 56
pathological complete response (56) 56
prognosis (56) 56
antibodies, monoclonal, humanized - adverse effects (55) 55
antineoplastic agents (55) 55
antineoplastic combined chemotherapy protocols - adverse effects (55) 55
antibodies, monoclonal, humanized (53) 53
antimitotic agents (52) 52
breast neoplasms - mortality (50) 50
medical prognosis (50) 50
antineoplastic agents - pharmacology (49) 49
surgery (48) 48
aged, 80 and over (47) 47
neoplasm metastasis (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1070) 1070
French (16) 16
German (11) 11
Czech (3) 3
Russian (2) 2
Spanish (2) 2
Bosnian (1) 1
Chinese (1) 1
Japanese (1) 1
Polish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 1712 - 1712
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 09/2016, Volume 34, Issue 26, pp. 3227 - 3227
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 5, p. e0217716
[This corrects the article DOI: 10.1371/journal.pone.0216095.]. 
Pertuzumab | ErbB-2 protein | Trastuzumab
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 34, pp. 56921 - 56931
We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in... 
HER2 positive | Metastatic breast cancer | T-DM1 | Previous pertuzumab | Real-world | PHASE-II | MONOCLONAL-ANTIBODY | PERTUZUMAB | DOCETAXEL | CHEMOTHERAPY | CELL BIOLOGY | real-world | GROWTH-FACTOR RECEPTOR | THERAPY | metastatic breast cancer | LAPATINIB PLUS CAPECITABINE | CLINICAL-PRACTICE | previous pertuzumab
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2014, Volume 111, Issue 10, pp. 1888 - 1898
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 61, pp. 31915 - 31919
Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another... 
Breast cancer | TDM1 | Pertuzumab | HER2 | Trastuzumab
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2019, Volume 30, Issue 6, pp. 921 - 926
Background In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed... 
early breast cancer | neoadjuvant | MULTICENTER | PERTUZUMAB PLUS TRASTUZUMAB | SAFETY | PHASE-II | ENDOCRINE THERAPY | OPEN-LABEL | BIOMARKER ANALYSIS | CHEMOTHERAPY | trastuzumab | LAPATINIB | HER2-positive breast cancer | ONCOLOGY | pertuzumab | EARLY BREAST-CANCER | Original
Journal Article
The Oncologist, ISSN 1083-7159, 02/2019, Volume 24, Issue 2, pp. e80 - e82
Human epidermal growth factor receptor 2 (HER2)‐targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression‐free... 
TRASTUZUMAB | ONCOLOGY | PERTUZUMAB | DOCETAXEL | STRESS-INDUCED CARDIOMYOPATHY
Journal Article
ONCOLOGY-NEW YORK, ISSN 0890-9091, 11/2015, Volume 29, Issue 11, pp. 797 - 797
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2015, Volume 13, Issue 12, pp. 1475 - 1485
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the... 
OVARIAN SUPPRESSION | 1ST-LINE TREATMENT | PERTUZUMAB PLUS TRASTUZUMAB | ONCOLOGY | PREOPERATIVE THERAPY | DOUBLE-BLIND | LETROZOLE | POSTMENOPAUSAL WOMEN | CHEMOTHERAPY | NEOADJUVANT | ANASTROZOLE
Journal Article
11/2009
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast cancers (BCs) and confers an aggressive tumour phenotype with a poor... 
Pertuzumab | Molecular Imaging | 0419 | Nuclear Medicine | HER2 | Breast Cancer | Trastuzumab
Dissertation
The Oncologist, ISSN 1083-7159, 06/2017, Volume 22, Issue 6, pp. 642 - 647
Background Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)‐positive breast cancer, but... 
Heart failure | Cardiotoxicity | Pertuzumab | Trastuzumab | ADJUVANT CHEMOTHERAPY | NSABP B-31 | PERTUZUMAB PLUS TRASTUZUMAB | HEART-FAILURE | FOLLOW-UP | OPEN-LABEL | PACLITAXEL | ONCOLOGY | ANTHRACYCLINE | ERBB2 | Breast Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2019, Volume 37, Issue 2, pp. 125 - 134
PurposeClinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's... 
ANDROGEN RECEPTOR | PLUS DOCETAXEL | CARBOPLATIN | PHARMACOKINETICS | ONCOLOGY | GLAND CARCINOMAS | COMBINATION | PERTUZUMAB | CANCER | CHEMOTHERAPY | PACLITAXEL | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.